Abstract
Objective-To determine whether interferon a-2a, when utilised as adjuvant chemotherapy following ablation of condylomata acuminata (genital warts) by cryotherapy, is effective in the prevention of recurrences. Design-Randomised, placebo-controlled, double-blind study. Statistical Patients were initially examined and a complete blood cell count, chemistry profile, urinalysis, and HIV ELISA antibody were performed before therapy. The number, distribution, and appearance of external condylomata were documented. Condylomata were measured in cubic millimeters of wart volume (greatest diameter x height of the perpendicular). One lesion was biopsied for histological confirmation and hybridisation for human papillomavirus (HPV) subtyping.
Assignment of patients to subcutaneous interferon (3 x 106 IU of interferon a-2a 3 times weekly x 8 weeks) (Roferon-A," Hoffmann-La Roche, Inc, Nutley, NJ) or placebo was determined by means of a computer-generated, randomised code. Those patients with disease duration less than nine months were assigned from drug code No 1 proceeding sequentially forward. Those with disease greater than nine months' duration were assigned from drug code No 100 working sequentially backwards, to accomplish equal stratification, with regards to disease duration.
All patients then received sufficient cryotherapy (liquid nitrogen-three freezethaw cycles once weekly) to clear visible warts. Interferon treatment began within two weeks of the last cryotherapy treatment. Study personnel taught the proper technique for subcutaneous self-administration of study medication utilising rotating sites (thigh, abdominal fat pad, and deltoid in sequence). They were treated and evaluated in a doubleblind fashion at post-interferon therapy months one, three, and six for disappearance or recurrence of their condylomata. Recurrences were considered an endpoint for evaluation of efficacy and those patients were no longer followed in the study. Analysis of results was performed by utilisation of Fisher's Exact Test (2-tailed).
Results
Of 97 patients originally entering the study, 49 were assigned to receive interferon and 48 placebo. The figure. There was no significant difference between these two groups (p = 099). Nor was there a difference in the total numbers of warts that recurred between the interferon and placebo groups. The interferon group had a median of 6.8 warts per patient pre-treatment and 3.3 at the conclusion of therapy while the placebo group had 7X8 and 4X8 warts.
Adverse drug reactions were noted in 43 of the 49 (88%) interferon recipients and in 20 of 48 (42%) placebo recipients. Adverse experiences resulting in withdrawal from the study included an influenza-like syndrome (fever, chills, headache, myalgia, and nausea) in three interferon and one placebo recipients, bronchospasm in one interferon recipient, and depression in one interferon recipient. Local reaction to the injection was noted in six interferon recipients and one placebo patient.
Discussion
We chose to study patients most of whom had received prior therapies a mean of 5.6 times in the interferon group and 4-5 times in the placebo group. Condylomata had been present a mean of 29-6 months in the interferon group and 34.7 months in the placebo group. Both of these factors are strongly correlated with recurrence. We treated a number of males with penile condylomata, a location often refractory to therapy. We chose to treat these patients with cryotherapy, a relatively less cytodestructive procedure than laser, because cryotherapy requires no local anaesthesia. We treated each wart an average of three times but 26 patients (12 interferon and 14 placebo recipients) took more than five treatments to clear which reflects the refractory nature of these warts. Our experience as well as othersb is that clearance rates of about 70% are obtained when cryotherapy is used an average of three times on nonrefractory condylomata (such as smaller condylomata present on wet mucosal surfaces for six months).
Following our ablation of condylomata with cryotherapy, many began to recur even prior to completion of the interferon adminis-1 1 tration (28% of the interferon group compared to 43% of placebo recipients). Further recurrence was noted in the six months following interferon therapy to the point where only 31% and 27% of each respective group remained free of active disease at the end of the study. As in our study, when cryotherapy was used in another study7 as the ablative technique, the addition of systemic interferon was no more effective than cryotherapy alone. Patients in this study were given interferon a2a 3 x 106 IU subcutaneously twice weekly versus placebo in addition to cryotherapy weekly for seven weeks. The interferon group had a clearance rate of 30% and the placebo group 40%.
While no benefit of interferon in the prevention of recurrence following ablation of condylomata with cryotherapy was noted in these studies, efficacy has been noted when laser is utilised. Using extended laser treatment, condylomata were removed and patients then received interferon a-2a or a-2b subcutaneously, 1 to 5 x 106 IU 3 times weekly for 4 to 10 weeks. Success rates of 23 to 40% in those treated with laser alone and 52 to 82% in those treated with laser plus interferon were observed. [8] [9] [10] The discrepancy between failed studies employing cryotherapy as the ablative procedure and successful ones utilising laser with adjuvant interferon may relate to the extension of laser treatment to the adjacent acetowhite areas which may harbour subclinical disease as a reservoir of human papillomavirus. This potential reservoir of virus if not destroyed by cryotherapy may then reinfect denuded areas of epithelium following treatment, resulting in recurrence of the condylomata. Certainly in the setting of suboptimal removal of recurrent condylomata with cryotherapy, subcutaneously administered interferon does not seem to have a systemic effect on prevention of recurrence of condylomata. If the results8-10 utilising laser with interferon as an adjuvant are reproducible in larger studies, it may be that laser in combination with systemic interferon
